Core Viewpoint - YS Biopharma Co., Ltd. is set to release its financial results for the first nine months of the fiscal year ending March 31, 2024, on April 19, 2024, before the U.S. market opens [1] Company Overview - YS Biopharma is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer [4] - The company has developed a proprietary PIKA® immunomodulating technology platform and a series of biologics aimed at improving vaccines for Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles [4] - YS Biopharma operates in multiple countries including China, the United States, Singapore, and the Philippines, and is led by a management team with extensive local and global experience in the biopharmaceutical industry [4] Earnings Conference Call - The management will hold an earnings conference call on April 19, 2024, at 8:00 A.M. Eastern Time to discuss the financial results [1] - Participants can access the call through various toll-free numbers provided for the United States, international, Mainland China, Canada, and Hong Kong [2] - A replay of the call will be available until April 26, 2024, along with a live and archived webcast on the company's investor relations website [3]
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024